Genexine, Inc. (KOSDAQ:095700)

Market Cap	186.47B -9.0%
Revenue (ttm)	5.81B -3.5%
Net Income	-54.53B
EPS	-1,320.62
Shares Out	45.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	216,939
Average Volume	475,104
Open	4,240.00
Previous Close	4,240.00
Day's Range	4,050.00 - 4,245.00
52-Week Range	4,065.00 - 7,490.00
Beta	n/a
RSI	29.81
Earnings Date	n/a

About Genexine

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 095700

Financial Performance

In 2023, Genexine's revenue was 4.43 billion, a decrease of -72.57% compared to the previous year's 16.14 billion. Losses were -66.87 billion, 19.5% more than in 2022.